H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ 8-K Current report, item 5.07 Accession Number: 0001104659-23-068730 Act: 34 Size: 212 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-23-065680 Size: 10 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-23-059389 Size: 10 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-23-055102 Act: 34 Size: 334 KB 网页链接
$Cytosorbents(CTSO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001410578-23-000868 Act: 34 Size: 6 MB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-23-050388 Act: 34 Size: 231 KB 网页链接
$Cytosorbents(CTSO)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-23-048425 Act: 34 Size: 1 MB 网页链接
$Cytosorbents(CTSO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-23-048432 Act: 34 Size: 1 MB 网页链接
$Cytosorbents(CTSO)$ ARS Annual Report to Security Holders Accession Number: 0001104659-23-048437 Act: 34 Size: 1 MB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001104659-23-047426 Act: 34 Size: 310 KB 网页链接